Skip to main content
Premium Trial:

Request an Annual Quote

Tabula Rasa, CQuentia Collaborate on PGx Delivery, Analytics

NEW YORK – Medication management technology vendor Tabula Rasa HealthCare said today that it is teaming with genetics testing laboratory and analytics software developer CQuentia to provide pharmacogenomics services and biometric wearables for patients and clinicians.

For the first part of the collaboration, Fort Worth, Texas-based CQuentia has chosen Moorestown, New Jersey-based Tabula Rasa's MedWise technology for electronic delivery of PGx test results to ordering physicians. MedWise goes beyond drug-gene pair analysis to  "inform precision across a patient's entire medication regimen," according to CQuentia CEO Alan Meeker.

"CQuentia has determined that TRHC's unique and valuable approach to incorporating PGx lab data into medication safety analysis makes TRHC the ideal partner to present PGx lab results to its clients," Meeker said in a statement.

At the same time, Tabula Rasa HealthCare has chosen CQuentia as its preferred PGx lab partner and has contracted for two proprietary assays, one for clinical use and another to support R&D of TRHC's medication risk mitigation technology. Tabula Rasa is building application programming interfaces to receive data directly from CQuentia's testing lab in Memphis, Tennessee, the companies said.

CQuentia also will provide unspecified biometric wearable products to THRC clients to "help inform further overall medication safety," Tabula Rasa Chairman and CEO Calvin Knowlton said.